• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

获得性血友病A与ST段抬高型心肌梗死（STEMI）：一种罕见的表现及治疗困境

Acquired Hemophilia A and ST-Elevation Myocardial Infarction (STEMI): A Rare Presentation and Management Dilemma.

作者信息

Yabut Jevin, Lima Gian, Vankina Ritika, Kumar Swarup, Meng Joyce

机构信息

Medicine, University of Connecticut, Farmington, USA.

Internal Medicine, University of Connecticut, Farmington, USA.

出版信息

Cureus. 2023 May 4;15(5):e38549. doi: 10.7759/cureus.38549. eCollection 2023 May.

DOI:10.7759/cureus.38549
PMID:37288205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10241663/
Abstract

Thrombotic events are a rare complication of recombinant activated factor VII (rFVIIa) therapy in patients with hemophilia. We present a case of a 71-year-old male who developed ST-elevation myocardial infarction after receiving rFVIIa replacement therapy for acquired hemophilia A.

摘要

血栓形成事件是血友病患者接受重组活化凝血因子VII（rFVIIa）治疗时罕见的并发症。我们报告一例71岁男性患者，其在接受rFVIIa替代疗法治疗获得性甲型血友病后发生了ST段抬高型心肌梗死。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d78/10241663/62b371c3f55f/cureus-0015-00000038549-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d78/10241663/13e343b9ab5c/cureus-0015-00000038549-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d78/10241663/fb39115c6a6f/cureus-0015-00000038549-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d78/10241663/e44228b46b4f/cureus-0015-00000038549-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d78/10241663/62b371c3f55f/cureus-0015-00000038549-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d78/10241663/13e343b9ab5c/cureus-0015-00000038549-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d78/10241663/fb39115c6a6f/cureus-0015-00000038549-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d78/10241663/e44228b46b4f/cureus-0015-00000038549-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d78/10241663/62b371c3f55f/cureus-0015-00000038549-i04.jpg

相似文献

1
Acquired Hemophilia A and ST-Elevation Myocardial Infarction (STEMI): A Rare Presentation and Management Dilemma.获得性血友病A与ST段抬高型心肌梗死（STEMI）：一种罕见的表现及治疗困境
Cureus. 2023 May 4;15(5):e38549. doi: 10.7759/cureus.38549. eCollection 2023 May.
2
[Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].[重组活化凝血因子VII（诺和七，诺和诺德公司）用于获得性凝血因子VIII抑制物血友病的止血治疗]
Schweiz Med Wochenschr. 1995 Mar 4;125(9):405-11.
3
Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases.应用重组活化凝血因子 VII 正确治疗获得性血友病 A 出血：7 例单中心研究
Int J Gen Med. 2016 Nov 3;9:393-399. doi: 10.2147/IJGM.S118422. eCollection 2016.
4
The Pharmacokinetics and Pharmacodynamics of A Novel Recombinant Activated Human Factor VII, GEN-0828, in Hemophilia B Mice.新型重组激活人因子 VII（GEN-0828）在血友病 B 小鼠中的药代动力学和药效学研究。
J Pharm Sci. 2023 Mar;112(3):877-883. doi: 10.1016/j.xphs.2022.12.013. Epub 2022 Dec 21.
5
Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.活化重组人凝血因子VII（rFVIIa）治疗对VIII因子有抑制性抗体患者的腹部出血。
Am J Hematol. 2000 Mar;63(3):109-13. doi: 10.1002/(sici)1096-8652(200003)63:3<109::aid-ajh1>3.0.co;2-o.
6
ST-Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII.一名接受艾美赛珠单抗和重组活化凝血因子 VII 治疗的甲型血友病患者发生 ST 段抬高型心肌梗死（STEMI）和肺栓塞
Haemophilia. 2020 Jan;26(1):e5-e8. doi: 10.1111/hae.13871. Epub 2019 Nov 6.
7
Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.重组活化凝血因子 VII（诺其）：用于急性、难以控制的危及生命的出血，作为替代疗法的补充。
Vox Sang. 2004 Jul;87(1):34-40. doi: 10.1111/j.1423-0410.2004.00533.x.
8
Potential role of recombinant factor VIIa as a hemostatic agent.重组凝血因子VIIa作为止血剂的潜在作用。
Clin Adv Hematol Oncol. 2003 Feb;1(2):112-9.
9
Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.重组活化凝血因子 VII 用于高滴度抑制物血友病患者重度膝关节手术及晚期膝关节炎的经济学评价：基于文献建模的探索性结果
Curr Med Res Opin. 2008 Mar;24(3):753-68. doi: 10.1185/030079908X273048. Epub 2008 Jan 29.
10
Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.rFVIIa（诺其）在先天性 A 型和 B 型血友病患者中对因子 VIII 或 IX 抑制剂的手术经验。
Haemophilia. 2011 Jul;17(4):579-89. doi: 10.1111/j.1365-2516.2010.02460.x. Epub 2011 Feb 7.

本文引用的文献

1
How to Manage a Patient with Haemophilia and ACS Requiring PCI: A Battle between Bleeding and Thrombosis.如何管理患有血友病且需要进行经皮冠状动脉介入治疗（PCI）的急性冠状动脉综合征（ACS）患者：出血与血栓形成之间的较量
Medicina (Kaunas). 2021 Apr 7;57(4):352. doi: 10.3390/medicina57040352.
2
Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC).在已批准适应症中，重组活化凝血因子VII（rFVIIa）引发的血栓形成事件罕见，且与老年、心血管疾病以及同时使用活化凝血酶原复合物浓缩剂（aPCC）有关。
J Blood Med. 2019 Sep 18;10:335-340. doi: 10.2147/JBM.S219573. eCollection 2019.
3
Percutaneous coronary intervention in patients with haemophilia presenting with acute coronary syndrome: an interventional dilemma: case series, review of the literature, and tips for management.
血友病患者急性冠状动脉综合征行经皮冠状动脉介入治疗：介入治疗的困境：病例系列、文献回顾及处理要点。
J Thromb Thrombolysis. 2013 Feb;35(2):271-8. doi: 10.1007/s11239-012-0802-y.
4
Management of acquired haemophilia A.获得性血友病 A 的治疗。
J Thromb Haemost. 2011 Jul;9 Suppl 1:226-35. doi: 10.1111/j.1538-7836.2011.04309.x.
5
Mechanism of action, development and clinical experience of recombinant FVIIa.重组活化凝血因子VII的作用机制、研发及临床经验
J Biotechnol. 2006 Aug 5;124(4):747-57. doi: 10.1016/j.jbiotec.2006.03.042. Epub 2006 May 12.